CARsgen Therapeutics(02171.HK): CT0596 Secures NMPA IND Approval for Treatment of R/R MM
NewTimeSpace News: On August 4, 2026, CARsgen Therapeutics(02171.HK) announced that CT0596 has been granted IND approval by the NMPA for the treatment of patients with relapsed/refractory multiple myeloma.
According to the announcement, CT0596 is currently under evaluation via investigator-initiated trials (IIT) in relapsed/refractory multiple myeloma or plasma cell leukaemia. The Company also plans to further explore its application in other plasma cell neoplasms and autoimmune diseases driven by autoreactive plasma cells.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CARSGEN-B (02171.HK): CT1190B and CT071 Abstracts Published at ASH 2026
- CARSGEN-B (02171.HK): Phase Ib Results of CT041 Consolidation Therapy in Gastric Cancer Presented at ESMO
- CARSGEN-B (02171.HK): First Patient Dose of CT0596 in China Phase I
- FWD (01828.HK): Buys 25% Stake in Bolttech Insurance (HK) for USD 20.72m
- TONTINE WINES (00389.HK): Wang He's Partial Cash Offer Lapses After Conditions Unmet on 2 October
